Dowling & Yahnke’s Eterna Therapeutics ERNA Stock Holding History

Dowling & Yahnke’s Portfolio ERNA Stock Details ERNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-2	Closed	-$285K	–	376
2021 Q2	$285K	Buy	+2	New	+$288K	0.02%	313

Other funds holding ERNA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CPWM

Cypress Point Wealth Management Dallas, Texas $492M AUM 22.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Dowling & Yahnke's ERNA Position: Q3 2021 in Review

Dowling & Yahnke sold out of Eterna Therapeutics (ERNA) in Q3 2021, closing a stake of 2 shares — an estimated $285K sold.

Dowling & Yahnke first reported a position in ERNA in Q2 2021 and held it in 1 quarter. The position peaked at $285K in Q2 2021. 44 funds tracked by Wall St. Rank hold ERNA as of Q3 2021.

Dowling & Yahnke reported no remaining Eterna Therapeutics position as of Q3 2021 after selling out during the quarter.
Dowling & Yahnke sold 2 Eterna Therapeutics shares in Q3 2021, an estimated $285K.
Dowling & Yahnke first reported a position in Eterna Therapeutics in Q2 2021 and held it in 1 quarter.
Dowling & Yahnke's Eterna Therapeutics position peaked at $285K in Q2 2021.
44 funds tracked by Wall St. Rank held Eterna Therapeutics as of Q3 2021.

Based on Dowling & Yahnke's 13F filing for Q3 2021, filed 12 Nov 2021.